Xperimentations.ca Bibliographie sur la

Transcription

Bibliographie sur la phencyclidine (PCP), Xperimentations.ca
Bibliographie sur la PCP
Abraham, H.D., A.M. Aldridge et P. Gogia. The psychopharmacology of hallucinogens,
Neuropsycopharmacology, vol. 14, 1996, p. 285–298.
Abramson, H.A., M. Jarvik, M. Kaufman, C. Kornestsky, A. Levine et M. Wagner. Lysergic
acid diethylamide (LSD-25): Physiological and perceptual responses, Journal of
Physiology, vol. 39, 1955, p. 3–60.
Barrett, S.P., C. Darredeau et R.O. Pihl. Patterns of simultaneous polysubstance use in drug
using university students, Human Psychopharmacology, vol. 21, 2006, p. 255–263.
Beach, H.J. Listening for the logos: A study of reports of audible voices at high doses of
psilocybin, Dissertation Abstracts International: Section B. The Sciences and
Engineering, vol. 57, 1997, p. 5316.
Boutros, N.N. et M.B. Bowers. Chronic substance-induced psychotic disorders: State of the
literature, Journal of Neuropsychiatry and Clinical Neurosciences, vol. 8, 1996, p.
262–269.
Carter, O.L., F. Hasler, J.D. Pettigrew, G.M. Wallis, G.B. Liu et F. Vollenweider. Psilocybin
links binocular rivalry switch rate to attention and subjective arousal levels in
humans, Psychopharmacology, vol. 195, 2007, p. 415–424.
Carter, O.L., J.D. Pettigrew, D.C. Burr, D. Alais, F. Hasler et F. Vollenweider. Psilocybin
impairs high-level but not low-level motion perception, NeuroReport, vol. 15, 2004,
p. 1947–1951.
Cerletti, A. Pharmacology of psilocybin. Article présenté lors de la première réunion
internationale de neuropsychopharmacologie, Rome, septembre 1958. Cité par Isbell,
H. Comparison of the reactions induced by psilocybin and LSD-25 in man,
Psychopharmacology, vol. 1, 1959, p. 29–38.
Cohen, S. Lysergic acid: Side effects and complications, Journal of Nervous and Mental
Disease, vol. 130, 1960, p. 30–39.
Coordination Centre for the Assessment and Monitoring of New Drugs. Risk assessment
report relating to paddos (psilocin and psilocybin), La Haye (Pays-Bas), 2000,
Coordination Centre for the Assessment and Monitoring of New Drugs. Cité par
Riley, S. et G. Blackman. Between prohibitions: Patterns and meanings of magic
mushroom use in the UK, Substance Use and Misuse, vol. 43, 2008, p. 55–71.
© Centre canadien de lutte contre l’alcoolisme et les toxicomanies | Mars 2012
Page 2 de 6
Creese, I., D.R. Burt et S.H. Snyder. The dopamine receptor: Differential binding of d-LSD
and related agents to agonist and antagonist states, Life Science, vol. 17, 1975, p.
1715–1719.
Delgado, P.L. et F.A. Moreno. Hallucinogens, serotin and obsessive compulsive disorder,
Journal of Psychoactive Drugs, vol. 30, 1998, p. 359–366.
Dobin, R. Dr. Leary’s Concord Prison Experiment: A 34-year follow-up study, Journal of
Psychoactive Drugs, vol. 30, 1998, p. 419–426.
Doblin, R. Pahnke’s “Good Friday Experiment”: A long-term follow-up and methodological
critique, Journal of Transpersonal Psychology, vol. 23, 1991, p. 1–28.
Erowid. Psilocybin mushrooms, 2005. Consulté sur le
www.erowid.org/plants/mushrooms/mushrooms.shtml.
Espiard, M.L., L. Lecardeur, P. Abadie, I. Halbecq et S. Dolfus. Hallucinogen persisting
perception disorder after psilocybin consumption: A case study, European
Psychiatry, vol. 20, 2005, p. 458–460.
Gouzoulis-Mayfrank, E., B. Thelen, L. Hermle et H. Sass. History, rationale, and potential of
human experimental hallucinogenic drug research in psychiatry,
Pharmacopsychiatry, vol. 31, 1998, p. 63–68.
Gouzoulis-Mayfrank, E., M. Schreckenberg, O. Sabri, C. Arning, B. Thelen, M. Spitzer, K.
Kovar, L. Hermle, U. Büll et H. Sass. Neurometabolic effects of psilocybin, 3,4Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in healthy
volunteers, Neuropsychopharmacology, vol. 20, 1999, p. 565–581.
Greenberg, G. Good trips, bad trips: Psychedelic drugs and dissociation. Dans S. Krippner et
S.M. Powers (éd.), Broken images, broken selves: Dissociative narratives in clinical
practice (p. 230–247), Philadelphie, Brunner/Mazel, 1998.
Griffiths, R.R., W.A. Richards, M.W. Johnson, U. McCann et R. Jesse. Mystical-type
experiences occasioned by psilocybin mediate the attribution of personal meaning and
spiritual significance 14 months later, Journal of Psychopharmacology, vol. 22, 2008,
p. 621–632.
Griffiths, R.R., W.A. Richards, U. McCann et R. Jesse. Psilocybin can occasion mysticaltype experiences having substantial and sustained personal meaning and spiritual
significance, Psychopharmacology, vol. 187, 2006, p. 268–283.
Grob, C.S. Psilocybin research with advanced-stage cancer patient, Multidisciplinary
Association for Psychedelic Studies Bulletin, vol. 15(3), 2005, p. 8.
Page 3 de 6
Halpern, J.H. et H.G. Pope. Do hallucinogens cause residual neuropsychological toxicity?,
Drug and Alcohol Dependence, vol. 53, 1999, p. 247–256.
Halpern, J.H. et H.G. Pope. Hallucinogen persisting perception disorder: What do we know
after 50 years?, Drug and Alcohol Dependence, vol. 69, 2003, p. 109–119.
Hasler, F., U. Grimberg, M.A. Benz, T. Huber et F. Vollenweider. Acute psychological and
physiological effects of psilocybin in healthy humans: A double blind, placebocontrolled dose-effect study, Psychopharmacology, vol. 172, 2004, p. 145–156.
Hermle L., M. Fünfgeld, G. Oepen, H. Botsch, D. Borchardt, E. Gouzoulis, R.A. Fehrenbach
et M. Spitzer. Mescaline-induced psychopathological, neuropsychological, and
neurometabolic effects in normal subjects. Experimental psychosis as a tool for
psychiatric research, Biological Psychiatry, vol. 32, 1992, p. 976–991.
Hofman, A. Chemical aspects of psilocybin; the psychotropic principle from the Mexican
fungus, Psilocybe Mexicana, article présenté à la première réunion internationale de
neuropsychopharmacologie, Rome, septembre 1958. Cité par Isbell, H. Comparison
of the reactions induced by psilocybin and LSD-25 in man, Psychopharmacology,
vol. 1, 1959, p. 29–38.
Holstein, F. Flashbacks: A personal follow-up, Archives of Psychiatry and Neurological
Sciences, vol. 222, 1976, p. 293–304.
Horgan, J. The Electric Kool-Aid clinical trial, New Scientist, vol. 185, 2005, p. 36-40.
Isbell, H. Comparison of the reactions induced by psilocybin and LSD-25 in man,
Psychopharmacology, vol. 1, 1959, p. 29–38.
Johnson, M.W., W.A. Richards et R.R. Griffiths. Human hallucinogen research: Guidelines
for safety, Journal of Psychopharmacology, vol. 22, 2008, p. 603–620.
Julien, R.M. A primer of drug action: A concise, nontechnical guide to the actions, uses, and
side effects of psychoactive drugs, New York, W.H. Freeman and Company, 1998.
Keeler, M.H. et C.B. Reifler. Suicide during an LSD reaction, American Journal of
Psychiatry, vol. 123, 1967, p. 884–885.
Kenna, J.C. et G. Sedman. The subjective experience of time during lysergic acid
diethylamide (LSD-25) intoxication, Psychopharmacologia, vol. 5, 1964, p. 280–288.
Lerner, A.G., M. Gelkopf, I. Skladman, I. Oyffe, B. Finkel, M. Sigal et A. Weizman.
Flashback and hallucinogen persisting perception disorder: Clinical aspects and
pharmacological treatment approach, Israel Journal of Psychiatry Relating Science,
vol. 29, 2002, p. 92–99.
Page 4 de 6
Maisto, S.A., M. Galizio et G.J. Connors. Drug use and abuse, Belmont (CA), Thomson
Higher Education, 2008.
Marsa, L. Acid test, Discover, vol. 29, 2008, p. 52–57.
Metzner, R. Teonanacatl: Sacred mushrooms of visions, El Verano (CA), FourTree Press,
2004.
Moreno, F.A., C.B. Wiegand, E.K. Taitano et P.L. Delgado. Safety, tolerability and efficacy
on psilocybin in 9 patients with obsessive-compulsive disorder, Journal of Clinical
Psychiatry, vol. 67, 2006, p. 1735–1740.
Pahnke, W. Drugs and mysticism: An analysis of the relationship between psychedelic drugs
and the mystical consciousness (thèse de doctorat, Université Harvard), 1963. Cité
par Doblin, R. Pahnke’s “Good Friday Experiment”: A long-term follow-up and
methodological critique, Journal of Transpersonal Psychology, vol. 23, 1991, p. 1–
28.
Passie, T., J. Seifert, U. Shnierder et M. Hinderk. The pharmacology of psilocybin, Addiction
Biology, vol. 7, 2006, p. 357–364.
Pierrot, M., P. Josse et M.F. Raspiller. Intoxications par champignons hallucinogènes,
Annales de Médecine Interne, vol. 151, 2000, p. 16–19.
Pollock, S.H. Liberty caps: Recreational hallucinogenic mushrooms, Drug and Alcohol
Dependence, vol. 1, 1975, p. 445–447.
Riley, S. et G. Blackman. Between prohibitions: Patterns and meanings of magic mushroom
use in the UK, Substance Use and Misuse, vol. 43, 2008, p. 55–71.
Schultes, R.E. Hallucinogens of plant origin, Science, vol. 163, 1969, p. 245–254.
Schwartz, R.H. et D.E. Smith. Hallucinogenic mushrooms, Clinical Pediatrics, vol. 27, 1988,
p. 70–73.
Sessa, B. Is it time to revisit the role of psychedelic drugs in enhancing human creativity?,
Journal of Psychopharmacology, vol. 22, 2008, p. 821–827.
Sewell, A.R., J.H. Hapern et H.G. Pope. Response of cluster headache to psilocybin and
LSD, Neurology, vol. 66, 2006, p. 1920–1922.
Siegal, R.K. Fire in the brain: Clinical tales of hallucination, New York, Dutton, 1992.
Stamets, P. Psilocybin mushrooms of the world: An identification guide, Berkeley (CA), Ten
Speed Press, 1996.
Page 5 de 6
Strassman, R. Adverse reactions to psychedelic drugs: A review of the literature, Journal of
Nervous and Mental Disease, vol. 172, 1984, p. 577–95.
Vollenwider, F., K.L. Leenders, C. Scharfetter, P. Maguire, O. Stadelman et J. Angst.
Positron emission tomography and fluorodeoxyglucose studies of metabolic
hyperfrontality and psychopathology in the psilocybin model of psychosis,
Neuropsychopharmacology, vol. 16, 1997, p. 357–372.
Vollenweider, F., M. Vollenweider-Scherpenhuyzen, A. Bäbler, H. Vogel et D. Hell.
Psilocybin induces schizophrenia-like psychosis in humans via a serontonin-2 agonist
action, NeuroReport, vol. 9, 1998, p. 3897–3902.
Wackermann, J., M. Wittman, F. Hasler et F. Vollenweider. Effects of varied doses of
psilocybin on time interval reproduction in human subjects, Neuroscience Letters,
vol. 435, 2008, p. 51–55.
Wapner, S. et D.M. Krus. Effects of lysergic acid diethylamide, and differences between
normals and schizophrenics on the Stroop Color-Word Test, Journal of
Neuropsychiatry, vol. 2, 1960, p. 76–81.
Wasson, R.G. The wondrous mushroom: Mycolatry in Mesoamerica, New York, McGrawHill Book Co., 1980.
Wasson, V.P. et R.G. Wasson. Mushrooms, Russia and history, New York, Pantheon Books,
1957.
Wittman, M., O. Carter, F. Hasler, B.R. Cahn, U. Grimberg, P. Spring, D. Hell, H. Flohr et F.
Vollenweider. Effects of psilocybin on time perception and temporal control of
behaviour in humans, Journal of Psychopharmacology, vol. 21, 2007, p. 50–64.
Wolbach, A.B., E.J. Miner et H. Isbell. Comparison of psilocin with psilocybin, mescaline
and LSD-25, Psychopharmacologia, vol. 3, 1962, p. 219–223.
Centre canadien de lutte contre l’alcoolisme et les toxicomanies
75, rue Albert, bureau 500 | Ottawa (Ontario) K1P 5E7 | Canada
Tél. : 613-235-4048 | Téléc. : 613-235-8101 | [email protected]
Page 6 de 6

Xperimentations.ca Bibliographie sur la

Transcription

Documents pareils

Xperimentations.ca Bibliographie sur la psilocybine

Xperimentations.ca Bibliographie sur la